Aroma Bit Receives Additional Capital Investment Funding From Epson X Investment, Kyocera, and TechAccel Ventures
9.2.2021 09:00:00 EET | Business Wire | Press release
Aroma Bit, Inc., (Representative Director & CEO: Shunichiro Kuroki, headquarters: Chuo-ku, Tokyo), develops and markets compact odor imaging sensors and various related innovative services, has allocated additional shares to third-parties. The purpose of the funding is to acquire growth funds needed for future functionality enhancements of the company’s compact odor sensors and development of mass production capabilities, business development, and etc. EB-GB Limited Partnership funded by Epson X Investment Corporation (Representative Director: Yasunori Ogawa, headquarters: Chiyoda-ku, Tokyo), Kyocera Corporation (President: Hideo Tanimoto, headquarters: Kyoto City, Kyoto), and TechAccel investment limited partnership 1 (fund operated by TechAccel Ventures, LLC (Functional Manager: Masatoshi Ohba, headquarters: Minato-ku, Tokyo)) are the investment partners participating in this new capital investment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210208005274/en/
Silicon CMOS type Smell Sensor Development Kit (Product ID: 5C-SSM) (Photo: Business Wire)
Aroma Bit, Inc.: http://www.aromabit.com
Purpose and background of the increased capital investment: Support for acceleration of the compact odor sensors’ mass production and expansion of the digital odor sensing market
Aroma Bit has developed the world’s first compact odor imaging sensor that digitizes odors with visualization patterns from various odor inputs, similar to an animal’s sense of smell. It differs from conventional gas sensors, which can only detect specific substances.
Despite COVID-19, Aroma Bit has seen an increase in business negotiations with customers both in Japan and internationally accelerated by emerging trends such as smart technology, contactless technology, and digital transformation (DX).
Furthermore, the device has a wide range of applications, including the food, agriculture, daily commodities, industrial machinery, mobility, healthcare, robotics, mobile information service, home electronics, and IoT industries. With market applications exceeding initial expectations, there is considerable potential demand for odor digitization using Aroma Bit’s innovative technology.
After this third-party allocation of new shares, Aroma Bit plans to collaborate with major electronic device companies with advanced manufacturing expertise to accelerate development and mass production of compact odor sensor technologies.
Additionally, Aroma Bit plans to strengthen development of new products and services that leverage the company’s proprietary odor databases, and expand its sales and marketing worldwide.
In the future, Aroma Bit will continue to pursue its vision of “Enrich Society by Creating a World where Odors and Aromas are Visualized through Digital Odor Sensing Technology.”
Release of development kit for silicon CMOS compact odor sensors
Aroma Bit launched its silicon CMOS sensor module development kit [5C-SSM-H1] in January of 2021. Those sensors feature 80 elements arranged on a 6 mm x 3 mm silicon chip (5 types of odor-sensitive membrane x 16 elements per membrane). Aroma Bit Silicon Sensor Technology, Inc., a subsidiary of Aroma Bit manages sales for these devices.
With the release of the silicon CMOS odor sensor, Aroma Bit anticipates increased demand in high-volume consumer applications such as mobile devices, mobility, and home electronics, where its other QCM odor sensor use was previously difficult due to factors such as price and usage environment.
About Aroma Bit
Aroma Bit is a company that plans, develops, and sells electronic devices such as compact odor sensors as well as innovative new services that use these devices.
|
[Company Profile] |
||
|
Company name: |
|
Aroma Bit, Inc. |
|
Location: |
|
Sagami Bldg. 2F, 7-13-6 Ginza, Chuo-ku, Tokyo |
|
Representative: |
|
Representative Director & CEO Shunichiro Kuroki |
|
Established: |
|
February 2014 |
|
Business: |
|
Development, production, and sales of electronic equipment and systems including compact odor imaging sensors |
|
|
|
Planning, development, and sales of products and innovative services that use the sensor products |
|
|
|
Other business related to the above |
|
URL: www.aromabit.com |
||
About Epson X Investment
Epson X Investment Corporation is a Corporate Venture Capital (CVC) firm wholly owned by information equipment and precision instrument manufacturer Seiko Epson Corporation. It established the “EP-GB Investment Limited Partnership” with independent venture capital firm Global Brain Corporation, which has strengths in CVC operations, as general partner and is conducting investment activities.
URL: https://www.epson-exi.com/
Kyocera Corporation (TOKYO:6971, https://global.kyocera.com/), the parent and global headquarters of the Kyocera Group, was founded in 1959 as a producer of fine ceramics (also known as “advanced ceramics”). By combining these engineered materials with metals and integrating them with other technologies, Kyocera has become a leading supplier of industrial and automotive components, semiconductor packages, electronic devices, smart energy systems, printers, copiers, and mobile phones. During the year ended March 31, 2020, the company’s consolidated sales revenue totaled 1.6 trillion yen (approx. US$14.7 billion). Kyocera is ranked #549 on Forbes magazine’s 2020 “Global 2000” list of the world’s largest publicly traded companies.
About TechAccel Ventures
TechAccel Ventures, LLC is a venture capital firm established and operated by Omron, Ricoh, and SMBC Venture Capital. It invests mainly in tech venture companies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210208005274/en/
Contact information
[Inquiries regarding this announcement]
Aroma Bit, Inc.
Public Relegations Department (Matsumoto, Osamu)
TEL: +81-3-4455-4609 / Email: info@aromabit.com
Epson X Investment Corporation
Seiko Epson PR & IR Department (Muto, Nobuo)
TEL: +81-266-58-1705 or +81-3-5368-0961 / Email: info@press.epson.co.jp
KYOCERA Corporation
Corporate Communications (Usami, Masaru)
TEL: +81-75-604-3514 / Email: webmaster.cc@kyocera.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Landmark Global Galderma Survey Shows 9 out of 10 People Are Affected by Skin Quality Concerns7.7.2026 08:00:00 EEST | Press release
Galderma (SWX:GALD) has unveiled results from the world’s most extensive skin quality profiling survey, finding that skin quality concerns are widespread, can impact emotional wellbeing and, while differing based on the individual, are often similar among people alike in age, lifestyle, and environment.1 These results underscore the need for effective solutions that can be tailored to a wide variety of skin quality concerns. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706426842/en/ Key findings:1 Nine out of ten people globally are affected by skin quality concerns, with each person experiencing an average of two concerns in the past month The most common concerns are fine lines and wrinkles (41%), dry skin (40%), and dull skin (37%), most frequently affecting the face Skin quality impacts quality of life for 85% of people, with more than one in three reporting feelings of self-consciousness, insecurity or anxiety Skin
Morinaga Milk Achieves Self-Affirmed GRAS Status for LAC-Living+™, Expanding U.S. Opportunities for Its Postbiotic Ingredient7.7.2026 05:00:00 EEST | Press release
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy and functional ingredient company, today announced that it has achieved self-affirmed GRAS (Generally Recognized As Safe) status in the United States for LAC-Living+™ (L. helveticus MCC1848), its proprietary postbiotic ingredient. This milestone expands the commercial availability of LAC-Living+ in the U.S. market and enables its use in dietary supplements, functional foods, and beverages, supporting the development of products designed to address growing consumer demand for health and well-being solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706806943/en/ Growing Interest in Postbiotics and Mental Well-Being Consumer interest in proactive health management has expanded significantly in recent years, alongside increasing awareness of the connection between the gut and the brain, commonly referred to as the gut–brain axis. As a result, the g
Access Advance Welcomes New Licensors to the Video Distribution Patent Pool7.7.2026 03:00:00 EEST | Press release
Access Advance LLC today announced that Sharp, M&K Holdings, Tagivan and 9 other patent owners who own substantial video codec patent portfolios that cover the core technologies behind video decoding, processing, and streaming media delivery, have joined the Video Distribution Patent Pool (VDP Pool) in the first half of 2026. "The addition of all of these new Licensors’ patent portfolios is a real win for both the VDP Pool and our many existing and future Licensees,” said Peter Moller, CEO of Access Advance. “These companies have broad and deep patent portfolios and further enhance the program’s market leading position in resolving the licensing issues around the use of modern video codecs across all the diverse business models of internet video streaming.” The following patent holders have joined the VDP Pool as Licensors in the first half of 2026: Digital Insights Inc. Hanbat National University Industry-Academic Cooperation Foundation Hanwha Vision Co., Ltd. Industry-Academy Coopera
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 02:00:00 EEST | Press release
Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Kath Harrison, Group President, International Growth at Real Chemistry. “By bringing Spurwing into Real Chemistry,
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 23:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706876183/en/ Crinetics’ marketed medicine, PALSONIFY® (paltusotine), received approval from the U.S. Food and Drug Administration (FDA) in September 2025. PALSONIFY was recently approved by the European Medicines Agency (EMA) a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom